Meta‐analysis of the molecular associations of mucinous colorectal cancer. BJS 2019; 106: 682-691.
Published: 4th April 2019
Authors: I. S. Reynolds, S. J. Furney, E. W. Kay, D. A. McNamara, J. H. M. Prehn, J. P. Burke et al.
Mucinous differentiation occurs in 5–15 per cent of colorectal adenocarcinomas. This subtype of colorectal cancer responds poorly to chemoradiotherapy and has a worse prognosis. The genetic aetiology underpinning this cancer subtype lacks consensus. The aim of this study was to use meta‐analytical techniques to clarify the molecular associations of mucinous colorectal cancer.
This study adhered to MOOSE guidelines. Databases were searched for studies comparing KRAS, BRAF, microsatellite instability (MSI), CpG island methylator phenotype (CIMP), p53 and p27 status between patients with mucinous and non‐mucinous colorectal adenocarcinoma. A random‐effects model was used for analysis.
Data from 46 studies describing 17 746 patients were included. Mucinous colorectal adenocarcinoma was associated positively with KRAS (odds ratio (OR) 1·46, 95 per cent c.i. 1·08 to 2·00, P = 0·014) and BRAF (OR 3·49, 2·50 to 4·87; P < 0·001) mutation, MSI (OR 3·98, 3·30 to 4·79; P < 0·001) and CIMP (OR 3·56, 2·85 to 4·43; P < 0·001), and negatively with altered p53 expression (OR 0·46, 0·31 to 0·67; P < 0·001).
The genetic origins of mucinous colorectal adenocarcinoma are predominantly associated with BRAF, MSI and CIMP pathways. This pattern of molecular alterations may in part explain the resistance to standard chemotherapy regimens seen in mucinous adenocarcinoma.Full text
You may also be interested in
Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer.
Authors: T. Akiyoshi, N. Tanaka, K. Kiyotani, O. Gotoh, N. Yamamoto, K. Oba et al.
BRAF mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases.
Authors: J.‐B. Bachet, N. Moreno‐Lopez, L. Vigano, U. Marchese, M. Gelli, L. Raoux et al.
Propensity score‐matched analysis of oncological outcome between stent as bridge to surgery and emergency resection in patients with malignant left‐sided colonic obstruction.
Authors: F. J. Amelung, W. A. A. Borstlap, E. C. J. Consten, J. V. Veld, E. E. van Halsema, W. A. Bemelman et al.
Authors: A. Zaborowski, A. Stakelum, D. C. Winter
Authors: Z. Lakkis, D. Vernerey, D. Mege, J.‐L. Faucheron, Y. Panis, J.‐J. Tuech et al.
Association between surgeon special interest and mortality after emergency laparotomy. BJS 2019; 106: 940-948.
Authors: H. Boyd‐Carson, B. Doleman, P. J. J. Herrod, I. D. Anderson, J. P. Williams, J. N. Lund et al.
Incidence and lifetime risk of hospitalization and surgery for diverticular disease. BJS 2019; 106: 930-939.
Authors: F. Sköldberg, J. Granlund, A. Discacciati, F. Hjern, P. T. Schmidt, O. Olén et al.
Bowel dysfunction after sigmoid resection for cancer and its impact on quality of life. BJS 2019; 106: 805-805.
Authors: H. Elfeki, H. M. Larsen, K. J. Emmertsen, P. Christensen, M. Youssef, W. Khafagy et al.
Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. BJS 2019; 106: 728-728.
Authors: B. Shinkins, J. N. Primrose, S. A. Pugh, B. D. Nicholson, R. Perera, T. James et al.
Randomized clinical trial
Randomized clinical trial of liposomal bupivacaine transverse abdominis plane block versus intrathecal analgesia in colorectal surgery. BJS 2019; 106: 692-699.
Authors: D. T. Colibaseanu, O. Osagiede, A. Merchea, C. T. Ball, E. Bojaxhi, J. K. Panchamia et al.
Impact of enhanced recovery on oncological outcomes following minimally invasive surgery for rectal cancer. BJS 2019; 106: 922-929.
Authors: B. J. Quiram, J. Crippa, F. Grass, J. K. Lovely, K. T. Behm, D. T. Colibaseanu et al.
Multicentre study of non‐surgical management of diverticulitis with abscess formation. BJS 2019; 106: 458-466.
Authors: D. P. V. Lambrichts, H. E. Bolkenstein, D. C. H. E. van der Does, D. Dieleman, R. M. P. H. Crolla, J. W. T. Dekker et al.